•   
  •   

Health & Fitness Covid-19: Antibody treatment shows promise for preventing Covid in care homes

23:11  21 january  2021
23:11  21 january  2021 Source:   msn.com

Eli Lilly ends antibody trial early after failed to help in recovery

  Eli Lilly ends antibody trial early after failed to help in recovery NIH officials say they found no safety concerns regarding Eli Lilly's antibody treatment but that there was no difference between patients receiving the drug and those getting a placebo.The ACTIV-3 study of the antibody LY-CoV555 (also known as bamlanivimab) was paused on October 13 due to 'potential safety concerns' and out of an 'abundance of caution.

Antibody treatments could serve as a complementary tool to help health care professionals fight Covid - 19 in their patients. Unlike vaccines, antibody treatments don’t produce lasting protection against a disease. Instead, they are meant to equip bodies with tools to immediately

An antibody treatment designed to protect against coronavirus could be available as early as this fall -- but only for a fraction of the millions of Americans who might benefit from the treatment .

A monoclonal antibody treatment substantially reduced the risk of getting Covid in care home residents and may have cut the risk of death in those who already had the virus, according to a trial of the drug.

a group of people wearing costumes: Of 299 residents, those who received the drug had up to an 80 per cent lower risk of contracting Covid-19, according to a study (Photo: Getty) © Provided by The i Of 299 residents, those who received the drug had up to an 80 per cent lower risk of contracting Covid-19, according to a study (Photo: Getty)

The drug, known as bamlanivimab, was developed by the US company Eli Lilly.

Of 299 residents, those who received the drug had up to an 80 per cent lower risk of contracting Covid-19, according to a study released ahead of publication because of the potential importance of its findings.

Regeneron pauses one of its coronavirus antibody drug trials

  Regeneron pauses one of its coronavirus antibody drug trials For the second time this month, a study testing an experimental antibody - this time, Regeneron's - drug for COVID-19 has been paused to investigate a possible safety issue in hospitalized patients. On Monday, the NIH said no safety problem had been verified, but they stopped the study because the drug didn't seem to work in that situation.'These kinds of results are informing us about the timing of the benefit,' said Dr. Myron Cohen, a University of North Carolina virologist who advises the government on COVID-19 treatments.

prevention , treatment , vaccine covid 19 , dexamethasone, coronavirus vaccine developments, monoclonal antibodies , convalescent plasma, and more). MEDIA CONTACT: Roger Seheult, MD Board Certified in Internal Medicine, Pulmonary Disease, Critical Care , and Sleep Medicine.

Companies are developing COVID - 19 treatments using monoclonal antibodies , Y-shaped immune Lilly also stressed that people receiving its antibody were shown to have fewer hospitalizations or Additional studies of their monoclonal treatments are underway in hospitalized COVID - 19 patients

Meanwhile, among 41 residents who already tested positive for the virus, none died after receiving the drug compared to 4 deaths in the placebo group.

Exceptionally pleasing results

“We are exceptionally pleased with these positive results, which showed bamlanivimab was able to help prevent COVID-19, substantially reducing symptomatic disease among nursing home residents, some of the most vulnerable members of our society,” said Lilly’s chief scientific officer, Daniel Skovronsky.

a group of people in a room: The drug, bamlanivimab, may reduce the number of people from care homes who become seriously ill with Covid (Photo: Reuters) © Provided by The i The drug, bamlanivimab, may reduce the number of people from care homes who become seriously ill with Covid (Photo: Reuters)

“These findings strengthen our conviction that monoclonal antibodies such as bamlanivimab can play a critical role in turning the tide of this pandemic,” he said.

U.S. to begin distributing Regeneron's COVID-19 antibody therapy...

  U.S. to begin distributing Regeneron's COVID-19 antibody therapy... Regeneron's treatment was given emergency use authorization by the FDA on Saturday, shortly after the status was given to Eli Lilly's drug. Officials plan to distribute 200,000 courses by the end of the year.Regeneron's antibody cocktail is the same drug that President Trump was given, and which he hailed a 'cure' (it has shown significant benefit in clinical trials, but there is no evidence it is a cure). Trump urged the drug's approval and promised to make it free to any American who needed it.

Our picks for COVID - 19 : how to treat coronavirus at home . A proportion of people who contract COVID - 19 will require hospital care - the likelihood of this is very low Even under the new measures announced by the government to prevent people from leaving their homes for non-essential

Covid - 19 IFRs are strongly age-dependent, with a steep increase above the age of 70. The median age of covid -related deaths in most Western countries In most Western countries, about half of all deaths occurred in nursing homes (see section 5). In terms of covid - 19 IFRs, an important difference exists

Experts in the field who were not involved in the research welcomed its findings – although they cautioned that the number of people involved in the study was quite small, the length of follow-up quite short at 8 weeks and that  more work needed to be done to verify them.

Expert reaction

Nick Cammack, Covid-19 therapeutics accelerator lead at Wellcome, said:“The monoclonal antibodies developed for Covid-19 have always held great promise, as they are the first treatments that are specific to the disease.  These results exceed our expectations, demonstrating that this class of treatments can be used to both prevent and treat disease.”

Professor Chris Butler, of the University of Oxford, added: “These preliminary findings are very exciting, in that they appear to show a benefit from monoclonal antibody treatment for prevention of SARS-CoV-2 infection.”

“While the potential findings about mortality are intriguing, there’s not enough data to come to any firm conclusions apart from that more research appears well justified,” he said.

“But this is tremendous news, in that nursing home residents and residents of long term care facilities have been hardest-hit by the pandemic and here we have an intervention that may well prevent the illness, as well as possibly be useful as an early treatment, in both staff and residents,” he added.

Scottish care home where 19 residents died in Covid outbreak slammed .
Staff at Lomond Court Nursing Home in Glenrothes, Fife, left clean laundry on the floor and uncovered milk and food in a dirty fridge that was not connected to power. The Care Inspectorate raised serious concerns and judged the home's care and support as weak. Lomond Court provides 24-hour nursing care and support to 40 older people with mental frailty but almost half the residents died during one of the worst Covid-19 outbreaks in Fife. The inspectorate said: 'Levels of cleanliness were poor and required immediate attention to help minimise the potential spread of infection.

usr: 0
This is interesting!